What is extraordinary about the ATRIPLA campaign cannot be defined in the language of the past. Like much of the breakthrough digital work today, the content and technological innovation of the ...

Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Diversify Advisory Services LLC trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 16.3% during the fourth quarter, Holdings Channel.com reports. The fund owned 2,513 shares of ...

Michael Yee, an analyst from Jefferies, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target remains the same with $115.00. Discover outperforming ...